Clinics in Dermatology
Volume 26, Issue 5 , Pages 460-463 , September 2008

Psoriatic arthritis: therapeutic principles

  • Martin Feuchtenberger, MD

      Affiliations

    • Corresponding Author InformationCorresponding authors. Martin Feuchtenberger and Christian Kneitz are to be contacted at the Department of Rheumatology and Clinical Immunology, University of Würzburg, Klinikstrasse 6, D-97070 Würzburg, Germany. Tel.: +49 0 931 201 70420; fax: +49 0 931 201 70421.
    web address
    • ,
  • Stefan Kleinert
    • ,
  • Hans-Peter Tony, MD
    • ,
  • Christian Kneitz, MD

      Affiliations

    • Corresponding Author InformationCorresponding authors. Martin Feuchtenberger and Christian Kneitz are to be contacted at the Department of Rheumatology and Clinical Immunology, University of Würzburg, Klinikstrasse 6, D-97070 Würzburg, Germany. Tel.: +49 0 931 201 70420; fax: +49 0 931 201 70421.
    web address

References 

  1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78
  2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17
  3. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978;53:511–518
  4. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544–1552
  5. Gladman DD, Farewell VT, Kopciuk HA, Cook RJ. HLA antigens and progression in psoriatic arthritis. J Rheumatol. 1998;25:730–733
  6. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol. 1986;13:586–592
  7. Mease PJ. Psoriatic arthritis therapy advances. Curr Opin Rheumatol. 2005;17:426–432
  8. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis. 2005;64(Suppl 2):ii78–ii82
  9. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64:74–77
  10. Jones G, Brooks P, Crotty M. Interventions for treating psoriatic arthritis. Cochrane Database Syst Rev. 2000;3:CD000212
  11. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939–1950
  12. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcomes. J Rheumatol. 1995;22:241–245
  13. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–864
  14. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272
  15. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043[electronic publication 2006 Jan 26]
  16. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2007;66:163–168[electronic publication 2006 Oct 17]
  17. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol. 2006;18:347–353
  18. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol. 2004;140:366
  19. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–610
  20. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54/5:1638–1645

PII: S0738-081X(07)00265-9

doi: 10.1016/j.clindermatol.2007.11.005

Clinics in Dermatology
Volume 26, Issue 5 , Pages 460-463 , September 2008

Article Tools